The objective of this study was to contribute long-term safety data for infl iximab and other therapies in Crohn ' s disease (CD).
INTRODUCTION
Th e pharmacological management of Crohn ' s disease (CD), an immune-mediated infl ammatory disorder characterized by recurrent infl ammation in the gastrointestinal tract, is determined by the location, extent, and severity of disease; disease-related complications ( 1 ); and patient preference related to the frequency and route of medication administration ( 2 ) . In the past, therapeutic options were generally limited to aminosalicylates; antibiotics; immunosuppressive agents such as cortico steroids; and immunomodulators such as 6-mercaptopurine, azathioprine, and methotrexate. Over the past decade, tumor necrosis factor alpha (TNF-α ) antagonists have become available as treatment options. Infl iximab, adalimumab, and most recently certolizumab pegol are eff ective in inducing clinical remission and mucosal healing in patients with CD ( 3, 4 ) . When used in combination with immunomodulators, the early use of these biological therapies has been shown to induce remission more rapidly than the conventional " step-up " treatment, resulting in a more durable remission, decreased need for treatment with corticosteroids, and improved rates of mucosal healing ( 5 ) .
Serious Infection and Mortality in Patients With
All available therapies for CD have potential adverse side eff ects. For instance, corticosteroid therapy is associated with diabetes, hypertension, infection, and osteoporosis ( 6 ) , and treatment with immunomodulators may be complicated by rare but serious side eff ects that can include bone marrow suppression, hepatotoxicity, opportunistic infection, an increased risk of lymphoma, and pancreatitis ( 6 -8 ) . Also, as both corticosteroids and immunomodulators have broad eff ects on the immune system, patients receiving such treatment at higher doses and / or for prolonged periods of time may be at increased risk for serious or opportunistic infections ( 9, 10 ) .
Potential side eff ects of TNF-α antagonists include serious opportunistic infections, such as tuberculosis and histoplasmosis, which occur at a higher incidence when concomitant immunosuppression (particularly corticosteroids) is employed ( 11, 12 ) . Th e absolute incidence of opportunistic infections, however, is gene rally low, as are the incidences of other potential side eff ects of anti-TNF-α therapy, including malignancies, lymphomas, demyelinating disorders, and lupus-like disorders ( 11, 13, 14 ) . Th e rare occurrence of hepatosplenic T-cell lymphomas in infl ammatory bowel disease patients is associated with thiopurine immunomodulatory therapy (azathioprine or 6-mercaptopurine), used either as monotherapy or in combination with TNF-α antagonists ( 7, 11, 12 ) .
Based on the continued need to answer important safety questions related to anti-TNF-α therapy, the Crohn ' s Th erapy, Resource, Evaluation, and Assessment Tool (TREAT ™ ) registry was undertaken. Th e TREAT registry is a large, observational registry that was designed to examine the long-term clinical, economic, and humanistic outcomes of various treatment regimens, including infl iximab, used in the management of CD in community-based and academic practice settings in North America. We previously reported the initial safety fi ndings derived from the TREAT registry aft er an average of 1.9 years of follow-up ( 15 ) . Results of that earlier analysis indicated that mortality rates were similar for infl iximab-and other-treatments-only-treated patients (0.53 vs. 0.43 per 100 patient-years; relative risk (RR) ratio = 1.24, 95 % confi dence interval (CI) = 0.73, 2.10; P = 0.43). While results of an unadjusted analysis showed an increased risk of serious infection with infl iximab treatment, results of multivariate logistic regression analysis suggested that infl iximab was not an independent predictor of serious infection (RR = 0.99, 95 % CI = 0.64, 1.54; P = 0.97). Factors independently associated with serious infection included moderate-to-severe disease activity, prednisone treatment, and narcotic analgesic treatment ( 15 ) . Although the TREAT registry is ongoing, patient enrollment into the TREAT registry is complete, and all enrolled patients have been followed for at least 5 years. Results of analyses refl ecting data collected as part of the TREAT registry through February 2010 are reported herein.
METHODS

Study design
Th e TREAT registry is an ongoing, prospective, observational, multicenter, long-term registry of North American patients with CD. Th e registry was initiated in 1999 to evaluate the clinical safety outcomes of various treatment regimens, including infl iximab, in the management of CD. Approximately 350 gastroenterologists from both community-based and academic practice settings were each to enroll up to 150 patients, for a target enrollment of at least 5,000 patients. Physicians were generally identifi ed from the membership list of the Crohn ' s and Colitis Foundation Association. Patients enrolled in the registry are treated at the discretion of their physicians (i.e., a treatment protocol is not predefi ned). At the start of the registry, it was stipulated that physician participation in the registry could be withdrawn if patient enrollment requirements were not met, complete data were not submitted, or a physician left the practice or elected to discontinue registry participation.
Th e design of the TREAT registry was approved by the institutional review boards at each participating site, and all patients provided written informed consent before participation in the registry. Physicians or their designees have been paid a small honorarium on a per patient basis as compensation for administering the registry. Janssen Biotech, Inc. (Spring House, PA), the manufacturer of infl iximab, is the sponsor of the TREAT registry. Th e registry operates under the supervision and guidance of an Advisory Committee comprising several authors of this publication (GRL, BGF, RDC, BAS, and WJS) and the TREAT medical monitor (previously RHD and now XX).
Registry participants
Patients enrolled into the TREAT registry must have had a diagnosis of CD and could not be participating in any clinical trial. Upon TREAT ' s inception, both pediatric and adult patients were enrolled. However, the protocol was subsequently amended to limit enrollment to patients 18 years of age or older. Th e fi ndings reported herein include limited data for 80 pediatric patients (defi ned as patients < 18 years of age at the time of enrollment) who were subsequently discontinued early from the registry.
Th is report contains a summary of data collected for 6,273 patients, while a previous report cited 6,290 patients ( 15 ) . Seventeen patients included in the previous report were found to be duplicates, i.e., sites either enrolled the same patient twice or treated a patient who was being seen at another TREAT registry site. Th ese 17 patients are now excluded from the TREAT registry database.
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Registry evaluations
In this registry, patient data were collected at enrollment and then on a semi-annual basis (each January and July). Patients enrolled in the registry were to be followed for a minimum of 5 years. Patient demographic information and physicians ' assessments of overall patient health and disease severity were documented upon registry enrollment. Physicians assessed disease severity according to the American College of Gastroenterology Guidelines ( 16 ) as remission, mild-to-moderate, moderate-to-severe, or severe-to-fulminant.
A wide array of patient data were collected at the semi-annual follow-up visits, including disease severity, medication use, adverse events, and the dates and outcomes of each infl iximab infusion. Participating TREAT physicians were asked to provide information regarding an expansive list of specifi c adverse events, including infusion reactions, infections, and malignancies. Th e following infusion reaction adverse event terms were tracked: arthritis, cardiopulmonary symptoms, chills, headache, hypertension, hypotension, infl uenza-like illness, muscle spasm, nausea, pyrexia, and rash. All other infusion reactions were categorized as " other. " In addition, serious adverse events (SAEs), lymphoma, tuberculosis, congestive heart failure, hypersensitivity reaction, interstitial lung disease, amyotrophic lateral sclerosis, and changes in pregnancy status were to be documented as they occurred. Physicians were required to report SAEs within 24 h of occurrence. A detailed description of the SAE was also required, including dates of onset and resolution, designation of whether the SAE was expected or unexpected, the seriousness and intensity of the SAE, the relationship of the SAE to the underlying CD, concomitant CD medications or surgical procedures for CD related to the SAE, and SAE treatment and outcome.
Data analysis
Data from both active and discontinued (using data available through the last patient contact) patients are included in the data analyses. Th e cohort of 3,420 patients that received infl iximab within 12 weeks before enrollment, who were scheduled to receive infl iximab within 30 days of enrollment, or who received infl iximab at some other point in the registry is termed " infl iximab-treated patients. " As it is not possible to document infl iximab administration before participation in the registry, only patients who met the criteria outlined above are considered " infl iximabtreated " for data related to serious infections, infl iximab dosing, infusion reactions, and baseline patient / disease characteristics. Patients who did not receive infl iximab during the registry are grouped as having received " other-treatments-only " in these analyses. For analyses involving mortality, an additional 344 patients with infl iximab exposure > 3 but < 12 months before registry enrollment were also included to yield a total of 3,764 patients " ever-exposed " to infl iximab. Baseline demographic and disease characteristics are summarized using descriptive statistics. As such, means and s.d. ' s are employed for continuous variables (age, body mass index, years between CD diagnosis and enrollment), and frequencies and percentages are employed for categorical outcomes (gender, race, involved intestinal segment(s), disease severity, immunomodulator treatment, prednisone treatment, narcotic analgesic therapy, and health resource utilization). Corti costeroid therapy represents systemic corticosteroids (i.e., prednisone or equivalent) exclusively, and immunomodulator therapy represents treatment with azathioprine, 6-mercaptopurine, methotrexate, and / or cyclosporine.
Serious infections were defi ned as any event in the Medical Dictionary for Regulatory Activities System-Organ Class " Infections and Infestations " that met the standard criteria for a SAE, including any infection reported as " serious " by the investigator and any infection that required hospitalization. Commonly observed serious infections were defi ned as those occurring at an overall incidence > 0.01 / 100 patient-years of follow-up.
Th e rates of adverse events per 100 patient-years of follow-up were calculated for each medication category (infl iximab-treated vs. other-treatments-only-treated) as the quotient of the total number of on-therapy events and patient-years of exposure to medication multiplied by 100. Comparisons of the resulting incidences were accomplished via generation of an RR ratio and its corresponding 95 % CI; P -values were generated using Generalizing Estimation Equation methodology. For other treatment group comparisons, the Student t -test was used to test for equality of means across treatment groups, and the χ 2 test was employed to evaluate the association between treatment group and categorical variables.
Before data analysis, the TREAT Registry Advisory Board prespecifi ed that infections occurring within 3 months of an infl iximab infusion would be considered potentially related to infl iximab, while infections occurring outside of this timeframe would be considered not related to infl iximab. Further, a Cox proportional hazards model with time-varying covariates was used to determine the relative contribution (in the form of hazard ratios [HR] and 95 % CI) of diff erent factors to the occurrence of death and serious infection. Factors assessed included age, sex, race, diseased segment(s), disease severity, years between diagnosis and enrollment in the TREAT registry, and medication use. For mortality analyses, CD medications designated as " ever used " were obtained from all available 6-month data collection periods that occurred between enrollment and the time of death. Medication use during the period in which the death occurred was included in this analysis. For analysis of serious infection, CD medication use was defi ned as any use in the 6-month data collection period before the onset of the serious infection. Medication use during the period in which the infection occurred was not included in these analyses because medication start and stop dates were not collected for any medications other than infl iximab. Th erefore, it was unknown whether the medication was given before or aft er the event. Note that for covariate analyses involving data collected at 6-month intervals (e.g., 1 January -30 June, 1 July -31 December), the most current collection period before the 23 February 2010 data cutoff would have pertained to data collected through 31 December 2009.
Th e eff ect of length of exposure on the infl iximab safety profi le was assessed by grouping each adverse event according to
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the number of infl iximab infusions received by the patient before adverse event onset, i.e., 1 -3, 4 -9, 10 -24, or ≥ 25 infusions. Adverse events in patients not exposed to infl iximab or in infl iximabtreated patients but before the fi rst on-registry infl iximab infusion were categorized within the other-treatments-only group. Th e 3,156 patients with at least two 6-month data collection periods as of 23 February 2010 were included in these analyses.
Th e registry data collection forms received through 23 February 2010 were analyzed using SAS soft ware, Version 8.02 or higher of the SAS System for Windows (SAS Institute Inc., Cary, NC). Given the retrospective nature of several data analyses, no adjustments were made for multiple comparisons.
RESULTS
Patient disposition and baseline characteristics
Th is report contains a summary of data collected for 6,273 patients, all of whom have been followed in the TREAT registry for at least 5 years. Data presented in this report refl ect the time period from registry initiation (July 1999) through 23 February 2010. Patient enrollment was complete and closed as of 31 March 2004. Th e average duration of follow-up for all patients enrolled is currently 5.2 years. Infl iximab-treated patients were followed for 17,712 patient-years, compared with 13,251 patient-years of follow-up for the other-treatments-only group. As of 23 February 2010, 43.2 % ( n = 2,710) of enrolled patients were actively participating in the registry. Among these actively participating patients, the average duration of follow-up is currently 7.5 years. Both active and discontinued patients are included in this report. Th e most common reasons for patient discontinuation have been " patient lost to follow-up " (1,602 / 3,563, 45.0 % ) and reasons categorized as " other " (1,539 / 3,563, 43.2 % ), most of which were related to patient changes in care and changes in the physician ' s participation in the registry. Patient discontinuations are detailed in Figure 1 .
More patients were female (58.6 % ) than male (41.4 % ), and most patients were Caucasian (90.8 % ). Th e average patient age at the time of enrollment was 42.5 ± 14.7 years. Baseline demographic characteristics were similar between the infl iximab-treated and other-treatments-only groups, with the exception of infl iximabtreated patients being younger than patients in the other-treatments-only group ( P < 0.001) ( Table 1 ). Note that 80 patients who were younger than 18 years were enrolled and then subsequently discontinued when the registry entrance criteria were amended to include only patients age 18 or older.
A somewhat higher proportion of patients had been treated with infl iximab ( n = 3,420, 54.5 % ) than those who had received other-treatments-only ( n = 2,853, 45.5 % ). Approximately 90 % ( n = 2,986) of infl iximab-treated patients had received at least two infusions. Among the 53,003 infl iximab infusions documented, most (81.5 % ) were at a dose of 5 mg / kg. Patients in the infl iximabtreated group vs. the other-treatments-only group were more likely to have received prednisone (47.8 % vs. 31.4 % ), immunomodulators (52.0 % vs. 32.1 % ), antibiotics (32.0 % vs. 23.4 % ), narcotic analgesics (17.3 % vs. 9.1 % ), and antidepressants (13.5 % vs. 8.3 % ) within 1 year of registry enrollment ( P < 0.001) ( Table 1 ) .
Patients in the infl iximab-treated group also diff ered significantly from patients in the other-treatments-only group with regard to intestinal segment(s) aff ected by disease, disease severity, and health resource utilization in the year before enrollment Mild-moderate disease applies to ambulatory patients who are able to tolerate oral alimentation without manifestations of dehydration, toxicity (high fevers, rigors, and prostration), abdominal tenderness, painful mass, obstruction, or > 10 % weight loss. e Moderate-severe disease applies to patients who have failed to respond to treatment for mild-moderate disease or those with more prominent symptoms of fevers, signifi cant weight loss, abdominal pain or tenderness, intermittent nausea or vomiting (without obstructive fi ndings), or signifi cant anemia. f Severe-fulminant disease applies to patients with persistent symptoms despite the introduction of corticosteroids, or individuals presenting with high fever, persistent vomiting, evidence of intestinal obstruction, rebound tenderness, cachexia, or evidence of an abscess.
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( Table 1 ) . Specifi cally, patients who received infl iximab, compared with patients who received other-treatments-only, were more likely to have both their ileum and colon involved (44.4 % vs. 36.7 % ; P < 0.001), and to have moderate-to-severe (30.6 % vs. 10.7 % ; P < 0.001) or severe-to-fulminant (2.5 % vs. 0.6 % ; P < 0.001) disease at enrollment. Hospitalization in the year before enrollment for either surgical (17.4 % vs. 13.6 % ; P < 0.001) or medical (14.2 % vs. 8.8 % ; P < 0.001) management was also more common among infl iximab-treated patients compared with patients who received other-treatments-only.
Infusion reactions
Of the 3,420 registry patients in the infl iximab-treated group, 3,322 had data available for assessment of infusion reactions. Th ree percent (1,571 / 53,003) of infl iximab infusions were associated with an infusion reaction; 0.047 % of reactions were serious. Th e most common infusion reactions were headache (0.5 % ) and arthritis (0.4 % ) ( Table 2 ).
Mortality
One hundred and ninety-one (3 % ) of the 6,273 patients died over the course of registry participation; causes of death are detailed in Table 3 . Of these 191 patients, 109 had received infl iximab and 82 had received other-treatments-only, yielding similar time-adjusted mortality rates for patients who had received infliximab (0.58 per 100 patient-years; RR (95 % CI) of 0.96 (0.72, 1.28; P = 0.81) and those who had not (0.59 per 100 patient-years) ( Table 4 ) . Adjusted results of a multivariate regression analysis ( Table 5 ) ( Table 5 ) .
Serious infection
Unadjusted rates of serious infection within 3 months of treatment were 2.06 and 1.42 per 100 patient-years, respectively, for the infl iximab and other-treatments-only groups, yielding a RR (95 % CI) of 1.45 (1.10, 1.91) ( P = 0.008). In a broader analysis including serious infections that occurred outside of the 3-month timeframe, unadjusted rates of serious infection were 2.04 and 1.00 per 100 patient-years, respectively, for the infl iximab and other-treatments-only groups, yielding an RR (95 % CI) of 2.04 (1.45, 2.89) ( P < 0.001) ( Table 4 ). With the exception of six serious fungal infections (fi ve in the infl iximab group and one in the other-treatments-only group) and four serious mycobacterial infections (all in the infl iximab group) ( Table 6 ), all other serious infections were viral or bacterial in nature. Th e most commonly observed serious infections, defi ned as those occurring at an overall incidence > 0.01 / 100 patient-years of follow-up, are displayed in Table 7 . Without adjustment for other potential a For neoplasia and mortality, patients in the infl iximab-treated group received infl iximab during the registry before event onset, including the year before registration (i.e., patients " ever exposed " to infl iximab). For serious infections, patients in the infl iximab-treated group received infl iximab during the registry participation and before event onset, including the 12 weeks before registration. Patients could contribute data to both treatment groups depending on the date of fi rst infl iximab use.
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Over the course of the registry, a patient can contribute patient-years at risk to more than one medication or dosing category. c Data are available from the beginning of the registry (neoplasia and mortality) or beginning in 2002 (serious infections). d P value derived from Generalized Estimating Equations. e Note that one additional patient " ever exposed " (see footnote a of Table 3 ) to infl iximab died after 23 February 2010 and is not included in this table but is shown in Table 3 . The other-treatments-only group included all patients without infl iximab exposure within the previous 3 months. Table 4 . This represents diseased area at baseline, as disease area was not collected longitudinally. c This represents time-varying maximum severity between enrollment and the 6-month data collection period of the event or censoring. This represents time-varying medication use, and is defi ned as any use between enrollment and the 6-month data collection period before the event or censoring. e Immunomodulators include azathioprine, methotrexate, and 6-mercaptopurine.
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confounding factors (e.g., severity of CD and use of other immunosuppressive medications), the incidences of pneumonia, cellulitis, and perirectal abscess were higher among patients who had received infl iximab (0.24, 0.15, 0.11 / 100 patient-years, respectfully) within the previous 3 months than among patients who had not (0.14, 0.03, 0.03 / 100 patient-years, respectively; Table 7 ).
Adjusted results of multivariate regression analyses ( Table 8 ) indicated that moderate-to-severe disease severity was the strongest predictor of serious infection (HR = 2.24, 95 % CI = 1.57, 3.19; P < 0.001), while colon only involvement (vs. both ileum and colon involvement) was protective against the development of serious infections (HR = 0.73, 95 % CI = 0.54, 1.00; P = 0.046). When investigating medications used by patients with a serious infection relative to patients who did not have a serious infection, infl iximab treatment conferred a signifi cant HR of 1.43 (95 % CI = 1.11, 1.84; P = 0.006). Treatment with immunomodulators (HR = 1.23, 95 % CI = 0.96, 1.57; P = 0.10) was not a signifi cant predictor of serious infection, while narcotic analgesic (HR = 1.98, 95 % CI = 1.44, 2.73; P < 0.001) and prednisone (HR = 1.57, 95 % CI = 1.17, 2.10; P = 0.002) use were both signifi cant predictors of serious infection ( Table 8 ) .
Th ere was no evidence of an increase in the occurrence of serious infections with receipt of more infl iximab infusions. Specifically, the incidences of serious infections were 2.58, 2.16, 1.65, and 1.92 per 100 patient-years in association with receipt of 1 -3, 4 -9, 10 -24, and ≥ 25 infl iximab infusions, respectively. Escalation of the infl iximab dose from 5 to 10 mg / kg also had no important eff ect on the occurrence of serious infections (data not shown).
Pregnancy
Maternal and paternal (i.e., treated male partner) pregnancies were monitored for outcome and clinical condition of live births. For both female and male registry participants, the vast majority of pregnancies resulted in lives births, i.e., 83.1 % (118 / 142) and 95.3 % (41 / 43), respectively, for infl iximab-treated patients and 90.7 % (68 / 75) and 91.7 % (11 / 12), respectively, for patients receiving only other treatments. Among the maternal and paternal live births documented, the vast majority of babies were healthy with no defect or other adverse event, i.e., 92.4 % (109 / 118) and 90.2 % (37 / 41), respectively, for infl iximab-treated patients and 85.3 % (58 / 68) and 90.9 % (10 / 11), respectively, for patients receiving only other treatments. A more detailed analysis of pregnancy in the TREAT registry will be the subject of a separate publication.
Neoplasia
Th e incidences of neoplasia (including benign, malignant, and unspecifi ed growths) were similar between infl iximab-treated patients (0.78 per 100 patient-years) and patients who received other-treatments-only (0.85 per 100 patient-years), yielding an RR (95 % CI) of 0.90 (0.69, 1.18) ( P = 0.46) ( Table 4 ). While 
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DISCUSSION
We are reporting on the updated safety information acquired throughout the TREAT registry, which is a large, prospective, observational research program designed to address the longterm safety of medications, including infl iximab, used to treat CD. Th is report, which describes the analysis of the prespecifi ed follow-up period of at least 5 years per patient, is thus the principal registry report and updates previously reported fi ndings through ~ 2 years of registry participation. Consistent with the initial registry report ( 15 ) , with an average of 5.2 years of patient follow-up in this registry study, the occurrence of death has been similar between patients treated with infl iximab and those who have received other-treatments-only (0.58 vs. 0.59 per 100 patient-years, respectively; RR = 0.96, 95 % CI = 0.72, 1.28, P = 0.81). For both treatment groups, death rates remain below annual death rates for CD patients documented in epidemiological studies ( 17 -20 ) .
Results of multivariate logistic regression analyses indicated that age, prednisone use, and narcotic analgesic use were signifi cant predictors of death, while neither infl iximab treatment nor immuno modulator therapy predicted death in patients with CD. Th ese fi ndings are particularly notable given that patients treated with infl iximab had a worse prognosis at baseline. Although the multivariate model adjusted the HR estimate for known predictors of mortality, such as clinical disease activity, it could not account for unknown confounders associated with disease severity that likely would have conveyed a greater risk of death in the infl iximab group. However, improved control of disease activity in patients treated with infl iximab might have off set mortality risks related to therapy from other causes such as serious infection. A higher incidence of infections in general was observed in the infl iximab-treated patients relative to patients receiving other-treatments-only. However, infl iximab-treated patients in the TREAT registry had more severe CD at registry entry and also were more likely to be using other immunosuppressive agents or prednisone. Multivariate regression analyses indicated that moderate-to-severe disease activity was the strongest signifi cant predictor of serious infection (HR = 2.24, P < 0.001), followed by treatment with narcotic analgesics (HR = 1.98, P < 0.001), treatment with prednisone (HR = 1.57, P = 0.002), and then infl iximab treatment (HR = 1.43, P = 0.006). Th e statistical signifi cance of infl iximab in this regard is a new fi nding relative to the previous registry report ( 15 ) . It is of note that the increased risk of serious infection with infl iximab did not lead to a higher mortality risk. As mentioned, it is likely that infl iximab lessened the disease burden and thus counterbalanced any mortality risk that might have been associated with other causes such as serious infection. It should be noted that while this type of analysis allows the relative comparison of the risk associated with one immunosuppressive drug with that of another, it does not allow for the assessment of risk associated with various combinations of therapies. In addition, the analysis does not take into consideration contributing risk factors such as duration of use, dose, or cumulative exposure of a particular immunosuppressive agent or combination regimen. However, in an analysis that grouped serious infections according to the number of infl iximab infusions the patient had received before the event, there was no a more detailed analysis of malignancy in the TREAT registry will be the subject of a separate publication, as a top-level summary, the overall incidences of solid tumors (0.42 vs. 0.45 events per 100 patient-years), non-melanoma skin cancer (0.16 vs. 0.18 events per 100 patient-years), and lymphoma (0.05 vs. 0.06 events per 100 patient-years) were similar in infl iximabtreated patients and those who received other-treatments-only, respectively. Includes all patients who did not receive infl iximab within the previous 3 months.
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Safety Outcomes in CD Patients in the TREAT Registry age, lower levels of education, and non-Caucasian race predicted attrition ( 23 ) . In two other registries involving a total of 6,185 patients with rheumatoid arthritis who initiated etanercept treatment, patients with follow-up data available through year 5 ranged from 42 to 57 % across the registries ( 24 ) . We observed similar proportions of patients with available data through an average of 5.2 years of follow-up in the TREAT registry ( ~ 50 % of patients overall).
Another potential limitation of these data is that only medication use during the registry or during the period before enrollment was considered. It is possible that some patients categorized as other-treatments-only had received infl iximab in the more distant past. However, with regard to the risk for serious infection, the assessment of whether or not serious infections occurred within 3 months of an infl iximab infusion addresses this potential concern. In addition, the prior remote use of infl iximab is unlikely in most patients as the registry was initiated soon aft er infl iximab was approved and became available.
In conclusion, the results presented herein, derived from CD patients enrolled in the TREAT registry with an overall average of more than 5 years of follow-up, indicate that infl iximab does not confer an increased risk of mortality. Moderate-to-severe CD was the strongest predictor of serious infection, followed by treatment with narcotic analgesics, prednisone therapy, and infl iximab treatment. Th ere has been no indication that infl iximab is associated with an increased risk of neoplasia or an increased risk of fetal malformation in the TREAT registry.
evidence of an increase in the occurrence of serious infections with increasing number of infl iximab infusions.
Th e signifi cant eff ect of narcotic analgesic use on the risk of serious infection and mortality could result from such therapy serving as a proxy for patients with the most severe cases of CD, although we would anticipate that diff erences in disease severity would have been corrected by the multivariate regression analyses conducted. In addition, it could be that narcotic analgesic use, which is known to slow intestinal motility, yields longer gut processing times and thus longer periods of patient exposure to infection-causing organisms. Finally, it may also be possible that narcotic anal gesic use can mask the signs and symptoms of infections until they become serious.
When assessed on a " per infusion " basis, the incidences of infusion reactions were similar across the TREAT registry (1,571 / 53,003 or 3 % ) and previously conducted clinical trials of infl iximab in CD patients, i.e., 106 / 2,026 or 5 % in ACCENT I ( 21 ) and 70 / 1,728 or 4 % in ACCENT II ( 22 ) .
With an approximate average of 5.2 years of patient follow-up, based on the TREAT registry data, infl iximab does not appear to be associated with an increased risk of development of neoplasia in general or with an increased risk for the development of malignant solid tumors, non-melanoma skin cancer, or lymphoma. Th ere have been no signals indicating an increased risk of fetal malformation associated with infl iximab therapy analyses to date. Note that results of more detailed analyses of TREAT registry malignancy and pregnancy data will be reported in separate publications.
While registries generally allow a large number of patients to be followed prospectively in a " real-world " setting, they are not as rigorously monitored as randomized controlled studies. As such, it is possible that some SAEs occurred and were not captured in the registry and, thus, such events could be under-reported in the TREAT registry. However, most analyses performed involved comparisons between diff erent CD treatment regimens, and there is no evidence indicating that SAE reporting would be inconsistent between treatment groups, outside of the fact that maintenance infl iximab therapy requires regular offi ce visits and thus a stronger likelihood for adverse event reporting. Registries can also be limited by comprising a population that is not as " sick " as the general CD population, possibly leading to an under-representation of certain adverse events. To address this point, the rate of hospitalizations and surgeries in TREAT was compared with an age-matched (18 -65 years of age) general CD population (from the MedStat MarketScan 2003 insurance claims database). In this analysis, the proportions of TREAT registry participants who had at least one CD-related hospitalization was similar to (5.36 % vs. 5.15 % , respectively) and the proportion who had at least one CD-related surgery was higher than (3.95 % vs. 1.90 % , respectively) those observed in the MarketScan database (data not shown). Th ese data suggest that patients in the TREAT registry were representative of the general CD population.
Th e potential for patient attrition can also limit interpretation of registry data ( 23 ) . In an evaluation of 6,346 patients with rheumatoid arthritis who were followed semi-annually across 11 long-running databases, results of multivariable analyses indicated that younger
